Functionally, oncogenic BRAF drives persistent activation of the MAPK/ERK pathway, which attenuates upstream EGFR/RAS signaling and thereby perturbs antitumor immune surveillance at multiple stages of the cancer-immunity mechanisms [32,33,64]. The gene discussed is EGFR; the disease is cancer.